Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan D Licht

Showing results (21-30 of 172) with videos related to

Pageof 18
Sort By:
Cancer Cell|August 2, 2003
Histone deacetylase inhibitors in cancer therapy: is transcription the primary target?Ricky W Johnstone, Jonathan D Licht
Annual Review of Pharmacology and Toxicology|October 10, 2017
Targeting Epigenetics in CancerRichard L Bennett, Jonathan D Licht
Current Opinion in Hematology|April 26, 2017
Epigenetic regulatory mutations and epigenetic therapy for multiple myelomaDaphné Dupéré-Richer, Jonathan D Licht
Current Opinion in Hematology|December 18, 2004
Therapeutic intervention in leukemias that express the activated fms-like tyrosine kinase 3 (FLT3): opportunities and challengesDavid W Sternberg, Jonathan D Licht
The Journal of Clinical Investigation|April 4, 2007
HOX deregulation in acute myeloid leukemiaKim L Rice, Jonathan D Licht
Cancer Cell|January 18, 2014
From anecdote to targeted therapy: the curious case of thalidomide in multiple myelomaJonathan D Licht, Jake Shortt, Ricky Johnstone
Current Opinion in Oncology|October 2, 2007
Molecular characterization of acute myeloid leukemia and its impact on treatmentOlga Frankfurt, Jonathan D Licht, Martin S Tallman
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 4, 2005
The theoretical basis of transcriptional therapy of cancer: can it be put into practice?Ari M Melnick, Kerin Adelson, Jonathan D Licht
Therapeutic Advances in Hematology|April 24, 2013
Epigenetic therapy of hematological malignancies: where are we now?Relja Popovic, Mrinal Y Shah, Jonathan D Licht
Epigenomes|February 15, 2019
Targeting EZH2 in Multiple Myeloma-Multifaceted Anti-Tumor ActivityMohammad Alzrigat, Helena Jernberg-Wiklund, Jonathan D Licht
Pageof 18

Showing results (21-30 of 172) with videos related to

Sort By:
Pageof 18
Cancer Cell|August 2, 2003
Histone deacetylase inhibitors in cancer therapy: is transcription the primary target?Ricky W Johnstone, Jonathan D Licht
Annual Review of Pharmacology and Toxicology|October 10, 2017
Targeting Epigenetics in CancerRichard L Bennett, Jonathan D Licht
Current Opinion in Hematology|April 26, 2017
Epigenetic regulatory mutations and epigenetic therapy for multiple myelomaDaphné Dupéré-Richer, Jonathan D Licht
Current Opinion in Hematology|December 18, 2004
Therapeutic intervention in leukemias that express the activated fms-like tyrosine kinase 3 (FLT3): opportunities and challengesDavid W Sternberg, Jonathan D Licht
The Journal of Clinical Investigation|April 4, 2007
HOX deregulation in acute myeloid leukemiaKim L Rice, Jonathan D Licht
Cancer Cell|January 18, 2014
From anecdote to targeted therapy: the curious case of thalidomide in multiple myelomaJonathan D Licht, Jake Shortt, Ricky Johnstone
Current Opinion in Oncology|October 2, 2007
Molecular characterization of acute myeloid leukemia and its impact on treatmentOlga Frankfurt, Jonathan D Licht, Martin S Tallman
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 4, 2005
The theoretical basis of transcriptional therapy of cancer: can it be put into practice?Ari M Melnick, Kerin Adelson, Jonathan D Licht
Therapeutic Advances in Hematology|April 24, 2013
Epigenetic therapy of hematological malignancies: where are we now?Relja Popovic, Mrinal Y Shah, Jonathan D Licht
Epigenomes|February 15, 2019
Targeting EZH2 in Multiple Myeloma-Multifaceted Anti-Tumor ActivityMohammad Alzrigat, Helena Jernberg-Wiklund, Jonathan D Licht
Pageof 18